M.B., B.Ch. (1975), University of Witwatersrand, Johannesburg, South Africa
M.Sc. (1979), University of British Columbia, Vancouver, British Columbia, Canada
Entrepreneurial Experiences: Dr. Soon-Shiong is the Executive Director of the UCLA Wireless Health Institute, and Professor of Microbiology, Immunology, Molecular Genetics and Bioengineering at UCLA. He is a fellow of both the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada. He serves on the Board of Directors for the National Institute of Transplantation, the Technology Council for the Center for Cancer Nanotechnology Excellence at Northwestern University, which is part of the National Cancer Institute’s (NCI) five-year initiative for nanotechnology in cancer research. He serves on the RAND Health Board of Advisors and the President’s Council at RAND, the Board of Trustees for the Saint John’s Health Center, the Advisory Board of the California NanoSystems Institute at UCLA, the Advisory Board for the Institute for Technology Advancement (ITA) at UCLA School of Engineering, the Board of Councilors of the USC Viterbi School of Engineering, and the Arizona Commerce Authority Board. He is a founding board member of the Dossia Foundation, a non-profit consortium of large employers (Wal-Mart, AT&T, BP America, Intel, Pitney Bowes, Cardinal Health, Sanofi-Aventis, Applied Materials, and Vanguard) that seek to enhance consumer engagement in their own healthcare through use of personal health records. In 2009, he was appointed by Attorney General Cuomo to the board of FAIR Health, a new not-for-profit entity to facilitate nationwide reform of consumer reimbursement for out of network healthcare charges.
Assistant Professor (1983 – 1989) ,
Gastro-Intestinal Surgery Division, Department of Surgery, Medical Center, UCLA.
Associate Investigator (1984 – 1987),
Center for Ulcer Research & Education, UCLA/VA Wadsworth Medical Center.
Assistant Professor (1987 – 1989),
Department of Medicine, UCLA.
Director (1986 – 1989),
Pancreas Transplant Program, UCLA.
Visiting Scientist (1989),
Massachusetts Institute of Technology, Boston, Massachusetts.
Director ( 1992 – 1998),
Islet Transplant Program, National Institute of Transplantation.
Awards: Dr. Soon-Shiong’s research has been recognized by national and international awards such as the Association for Academic Surgery Award for Research, the American College of Surgeons Schering Scholar, the Royal College Physicians and Surgeons Research Award, the Peter Kiewit Distinguished Membership in Medicine Award, and the International J.W. Hyatt Award for Service to Mankind. Dr. Soon-Shiong received the 2006 Gilda Club Award for the advancement of cancer medicine and is a recipient of a 2007 Ellis Island Medal of Honor as well as the St. Mary Medical Center Life Achievement Award in 2007 and the St. John’s Health Center Caritas Award in 2007. In 2008, he received the Medical Visionary Award from the Pancreatic Cancer Action Network for his work in pancreatic cancer & the Los Angeles County Economic Development Council (LAEDC) Eddy Award in November 2009. The Los Angeles Business Journal recognized him as their 2010 Business Person of the Year, and the National Library of Medicine awarded Dr. Soon-Shiong the Distinguished Medical Science Award. The University of Arizona awarded him an honorary doctorate in December 2010, and Visiting Professor of the Imperial College of London in 2011.
He is currently chairman of the Chan Soon-Shiong Family Foundation and chairman and CEO of the Chan Soon-Shiong Institute for Advanced Health, National LambdaRail, the Healthcare Transformation Institute, NantWorks, LLC and NantOmics.
Since 2006, Dr. Soon-Shiong has turned his attention to transforming healthcare by establishing an integrated health information platform and founded the National Coalition for Health Integration (NCHI) to create a national health network for the secure, national sharing of biomedical information with the goal of improving health for individuals.
Dr. Soon-Shiong has also found the Institute for Advanced Health, which will provide high-speed computing capabilities for human genotyping to target specific cancer treatments, as well as technologies for the better management of chronic disease.